A balanced randomised placebo controlled blinded phase IIa multi-centre study to investigate the efficacy and safety of AUT00063 versus placebo in subjective tinnitus: the QUIET-1 trial
Hall, Deborah; Ray, Jaydip; Watson, Jeanette; Sharman, Alice; Hutchison, John; Harris, Peter; Daniel, Matija; Millar, Bonnie; Large, Charles H.
Charles H. Large
AUT00063 is an experimental new medicine that has been demonstrated to suppress spontaneous hyperactivity by modulating the action of voltage-gated potassium-channels in central auditory cortical neurons of a rodent model. This neurobiological property makes it a good candidate for treating the central component of subjective tinnitus but this has not yet been tested in humans. The main purpose of the QUIET-1 (QUest In Eliminating Tinnitus) trial was to examine the effect of AUT00063 on the severity of tinnitus symptoms in people with subjective tinnitus. The trial was a randomised, placebo-controlled, observer, physician and participant blinded multi-centre superiority trial with two parallel groups and a primary endpoint of functional impact on tinnitus 28 days after the first drug dosing day.
The trial design overcame the scale and logistical challenges of delivering a scientifically robust, statistically powered multi-centre study for subjective tinnitus within the National Health Service in England. The trial was terminated early for futility. Overall, 212 participants consented across 18 sites with 91 participants randomised to groups using age, gender, tinnitus symptom severity and hearing status as minimisation factors. While the pharmacokinetic markers confirm the uptake of AUT00063 in the body, within the expected therapeutic range, with respect to clinical benefit findings indicated that AUT00063 was not effective in alleviating tinnitus symptoms (1.56 point change in Tinnitus Functional Index). In terms of clinical harms, results indicated that a daily dose of 800mg capsules of AUT00063 taken for 28 days was safe and well tolerated. These findings provide significant advances in the drug development field for hearing sciences, but raise questions about the predictive validity of certain rodent models of noise-induced hearing loss and tinnitus, as least for the mechanism evaluated in the present study. Trial Registration: (EudraCT) 2014-002179-27; NCT02315508.
Hall, D., Ray, J., Watson, J., Sharman, A., Hutchison, J., Harris, P., …Large, C. H. (2019). A balanced randomised placebo controlled blinded phase IIa multi-centre study to investigate the efficacy and safety of AUT00063 versus placebo in subjective tinnitus: the QUIET-1 trial. Hearing Research, 377, 153-166. https://doi.org/10.1016/j.heares.2019.03.018
|Journal Article Type||Article|
|Acceptance Date||Mar 19, 2019|
|Online Publication Date||Mar 27, 2019|
|Deposit Date||Mar 20, 2019|
|Publicly Available Date||Apr 4, 2019|
|Peer Reviewed||Peer Reviewed|
Publisher Licence URL
You might also like
Gap-induced inhibition of the post-auricular muscle response in humans and guinea pigs